Compare Orchid Chemicals with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SUN PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SUN PHARMA ORCHID PHARMA LTD/
SUN PHARMA
 
P/E (TTM) x -0.4 509.5 - View Chart
P/BV x 0.1 3.1 3.7% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ORCHID PHARMA LTD   SUN PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SUN PHARMA
Mar-19
ORCHID PHARMA LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs194679 28.6%   
Low Rs35375 9.3%   
Sales per share (Unadj.) Rs276.5121.1 228.2%  
Earnings per share (Unadj.) Rs-79.213.4 -592.2%  
Cash flow per share (Unadj.) Rs-43.520.7 -210.1%  
Dividends per share (Unadj.) Rs02.75 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9172.6 31.3%  
Shares outstanding (eoy) m70.452,399.26 2.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.4 9.5%   
Avg P/E ratio x-1.439.4 -3.7%  
P/CF ratio (eoy) x-2.625.5 -10.3%  
Price / Book Value ratio x2.13.1 69.5%  
Dividend payout %020.6 0.0%   
Avg Mkt Cap Rs m8,0671,264,650 0.6%   
No. of employees `0002.817.5 16.0%   
Total wages/salary Rs m2,52759,671 4.2%   
Avg. sales/employee Rs Th6,956.116,608.1 41.9%   
Avg. wages/employee Rs Th902.53,409.6 26.5%   
Avg. net profit/employee Rs Th-1,993.01,833.8 -108.7%   
INCOME DATA
Net Sales Rs m19,477290,659 6.7%  
Other income Rs m40710,255 4.0%   
Total revenues Rs m19,884300,914 6.6%   
Gross profit Rs m1,10363,076 1.7%  
Depreciation Rs m2,51917,533 14.4%   
Interest Rs m5,2275,553 94.1%   
Profit before tax Rs m-6,23650,246 -12.4%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-12,144 -4.2%   
Tax Rs m-1256,009 -2.1%   
Profit after tax Rs m-5,58032,093 -17.4%  
Gross profit margin %5.721.7 26.1%  
Effective tax rate %2.012.0 16.8%   
Net profit margin %-28.711.0 -259.5%  
BALANCE SHEET DATA
Current assets Rs m11,014310,692 3.5%   
Current liabilities Rs m32,060173,396 18.5%   
Net working cap to sales %-108.147.2 -228.8%  
Current ratio x0.31.8 19.2%  
Inventory Days Days9599 95.8%  
Debtors Days Days34112 30.1%  
Net fixed assets Rs m29,440232,477 12.7%   
Share capital Rs m7052,399 29.4%   
"Free" reserves Rs m2,043411,691 0.5%   
Net worth Rs m3,800414,091 0.9%   
Long term debt Rs m9,01815,226 59.2%   
Total assets Rs m46,510646,938 7.2%  
Interest coverage x-0.210.0 -1.9%   
Debt to equity ratio x2.40 6,454.2%  
Sales to assets ratio x0.40.4 93.2%   
Return on assets %-0.85.8 -13.1%  
Return on equity %-146.97.8 -1,894.8%  
Return on capital %-3.710.2 -36.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51366,025 11.4%   
Fx outflow Rs m5,64938,610 14.6%   
Net fx Rs m1,86527,415 6.8%   
CASH FLOW
From Operations Rs m1,68221,965 7.7%  
From Investments Rs m-9,860-6,813 144.7%  
From Financial Activity Rs m6,644-27,305 -24.3%  
Net Cashflow Rs m-1,535-8,442 18.2%  

Share Holding

Indian Promoters % 32.3 63.7 50.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.1 89.7%  
FIIs % 3.3 23.0 14.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 8.3 666.3%  
Shareholders   84,811 133,026 63.8%  
Pledged promoter(s) holding % 54.9 0.5 10,362.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  STERLING BIOTECH  CADILA HEALTHCARE  ALEMBIC LTD  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS